[Evaluation of the protocol CMA reinforced in the treatment of endemic Burkitt lymphoma at CHU of Yopougon in Abidjan].
We report the results of the protocol CMA (cyclophosphamide, methotrexate, Aracytine) reinforced of 26 patients affected by Burkitt lymphoma in facial-maxillary localisation, in a retrospective study from January 2000 till December 2007 and prospective from January till September 2008. Their average age was 7.89 years, with a sex ratio of 2.71. The global response to the treatment was 92.3% with 57.7% of complete remission and 34.6% of incomplete remission. The morbidity related to treatment was essentially a haematological complication (84.6%) and hydroelectrolytic complication (84.6%). Evolution was made towards death in 30.8 and 15.4% were lost of view. The median monitoring was 18.2 months. Treatment response was linked to the therapeutic compliance (P < 0.001), and the delay of consultation (P = 0.01).
Tolo-Diebkilé
A
A
Service d'Hématologie Clinique, CHU de Yopougon, Abidjan, Côte-d'Ivoire, Côte-d'Ivoire. tolo_aissata@yahoo.fr
Koffi
G K
GK
Nanho
C D
CD
Sawadogo
D
D
Kouakou
B
B
Siransi-Bogui
L
L
Ayémou
R
R
Sanogo
I
I
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002051:Burkitt Lymphoma / Q000188:drug therapy* / Q000473:pathology; D002648:Child; D002675:Child, Preschool; D007560:Cote d'Ivoire; D003520:Cyclophosphamide / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D005153:Facial Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D008441:Maxillary Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008727:Methotrexate / Q000008:administration & dosage; D012074:Remission Induction
D003561:Cytarabine; D003520:Cyclophosphamide; D008727:Methotrexate